Clinical Fellowships
Alnylam's Clinical Fellowships fund U.S. academic training for physicians in diagnosing, treating, and researching Transthyretin-mediated (ATTR) Amyloidosis through multidisciplinary clinical programs.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships submission deadline)
Funding Amounts: Up to $95,000 per institution for a one-year fellowship; funds may be used for salary and benefits only.
Summary: Supports U.S. academic institutions in advancing physician training in Transthyretin-mediated (ATTR) Amyloidosis through multidisciplinary clinical fellowships.
Key Information: Only ACGME-accredited U.S. institutions with active Cardiology Fellowship Programs are eligible.
Description
Alnylam Pharmaceuticals' Clinical Fellowships program provides funding to U.S. academic institutions to support the education and training of physicians in the diagnosis, treatment, and research of Transthyretin-mediated (ATTR) Amyloidosis. The fellowship is designed to foster multidisciplinary collaboration, improve early recognition, optimize treatment pathways, and accelerate the translation of emerging science into patient-centered care. Funding is intended to support salary and benefits for fellows, with a focus on curriculum development and infrastructure to conduct successful clinical fellowship programs in ATTR Amyloidosis.
